Advaxis, Inc. To Participate In Canaccord Genuity Orphan Drug One-On-One Day

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRINCETON, N.J., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it will participate in the Canaccord Genuity Orphan Drug One-on-One Day, Monday, February 24, 2014 at the Omni Berkshire Place in New York.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC